Forget SpaceX's Upcoming Q2 Results. History Says You Should Wait at Least This Long Before Buying SpaceX Stock.

Historical data suggests investors should wait until mid-2027 or later before buying SpaceX stock, despite the company's recent IPO and operational achievements. Large IPOs typically underperform their market index by 4% over three years, and SpaceX's high P/S ratio of 76 (versus tech sector average of 9) indicates overvaluation. Additionally, accelerating capital expenditures in AI investments raise concerns about future returns.

07/31/2026, 3:19 PM • The Motley Fool

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Dyne Therapeutics, a clinical-stage neuromuscular disease company, announced a $300 million underwritten public offering of common stock with a 30-day option for underwriters to purchase an additional $45 million. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James are serving as joint book-running managers. The offering is subject to market conditions and SEC approval.

07/21/2026, 4:46 PM • GlobeNewswire

SpaceX Stock Has Stumbled Since Its IPO. History Says It Could Be Up by This Much in 1 Year.

SpaceX stock, which opened at $150 over a month ago, is now trading below that level. Based on 26 years of historical IPO data, large IPOs typically gain only 3.5-4% in their first year, suggesting SpaceX shares could reach around $156 within 11 months. The company faces headwinds including unprofitability, massive capital expenditures ($27 billion in 2025), risky bets on Starship rocket technology, and an unproven orbital AI data center plan. Analysts' price targets range from $300-$800, but historical trends suggest more modest gains.

07/16/2026, 3:06 AM • The Motley Fool

Bragar Eagel & Squire, P.C. is Investigating Jefferies Financial Group Inc. on Behalf of Jefferies Stockholders and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire is investigating Jefferies Financial Group for potential securities violations related to its Point Bonita Capital fund's $715 million exposure to bankrupt auto supplier First Brands. The investigation follows SEC inquiry into whether Jefferies adequately disclosed risks to investors. Jefferies stock declined significantly following multiple negative disclosures about the First Brands collapse and subsequent weak earnings reports.

07/14/2026, 6:37 PM • GlobeNewswire

Jefferies Financial Group, Inc. Investigated by the Portnoy Law Firm

The Portnoy Law Firm has initiated a securities fraud investigation into Jefferies Financial Group following significant losses tied to auto supplier First Brands' bankruptcy. Jefferies' Point Bonita Capital fund faced approximately $715 million in exposure to First Brands. The company took a $30 million loss and disclosed declining asset management fees and investment returns in Q2 2026 results, leading to multiple stock price declines totaling over 25% across several disclosure dates.

07/13/2026, 2:28 PM • GlobeNewswire

UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation

Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations related to false or misleading statements about FDA review of its OLC New Drug Application. The company received a second Complete Response Letter on June 30, 2026, citing manufacturing deficiencies, which led to a stock price decline. Investors who have suffered losses are encouraged to contact the firm.

07/13/2026, 2:05 PM • GlobeNewswire

ALHC ALERT: Block & Leviton Investigating Alignment Healthcare, Inc. For Possible Securities Fraud; Investors Should Contact Block & Leviton to Learn More

Block & Leviton is investigating Alignment Healthcare, Inc. (ALHC) for potential securities law violations following allegations that a former executive filed a whistleblower lawsuit claiming the company manipulated finances to boost stock price and executive compensation. The stock fell approximately 16.72% following the report. The firm is also investigating Jefferies Financial Group and Unicycive Therapeutics for similar violations.

07/08/2026, 5:47 PM • GlobeNewswire

Jefferies Reports Earnings Before the Big Banks. Here's Why Wall Street Should Be Watching Closely.

Jefferies Financial reported mixed Q2 earnings with net earnings and revenue missing estimates, but achieved record investment banking revenue of $1.2 billion (up 58% YoY). While asset management revenue declined 46% due to market weakness and Point Bonita losses, the strong investment banking results suggest upcoming quarters for Goldman Sachs, Morgan Stanley, and JPMorgan Chase should be robust, as they won't face the same asset management headwinds.

06/28/2026, 1:15 PM • The Motley Fool

History Says You Can Get a Better Deal on SpaceX Stock If You Wait This Long

SpaceX stock surged 20% on its IPO day and has continued climbing, but historical data suggests investors should wait before buying. Large IPOs that gain 26.5% in their first week typically only gain 3.5% over the following year. With SpaceX trading at a premium valuation (P/S of 130 vs. 10 for average tech stocks), waiting a year or so may yield better entry prices.

06/17/2026, 9:30 AM • The Motley Fool

JEF INVESTIGATION: Robbins Geller Rudman & Dowd LLP Launches Investigation into Jefferies Financial Group, Inc. and Encourages Investors and Potential Witnesses to Contact Law Firm

Law firm Robbins Geller is investigating Jefferies Financial Group for potential securities law violations related to false or misleading statements regarding First Brands' bankruptcy. Jefferies' Point Bonita Capital division is owed approximately $715 million from First Brands, and the company allegedly failed to disclose billions in off-balance-sheet debt during refinancing efforts.

06/05/2026, 10:15 PM • GlobeNewswire

Why Kratos Stock Dropped Again Today

Kratos Defense & Security Solutions stock dropped despite beating earnings, with five out of six analysts cutting price targets. The company reported 23% sales growth and doubled GAAP income, but continues to burn cash with negative free cash flow of $47.3 million. At a valuation of 340 times earnings, analysts remain skeptical despite strong order book growth driven by increased drone demand in global conflicts.

05/11/2026, 10:02 AM • The Motley Fool

Suja Life Announces Pricing of Initial Public Offering

Suja Life, Inc. announced the pricing of its IPO at $21.00 per share for 8,888,889 shares of Class A common stock. The company expects to raise approximately $173.6 million in net proceeds, which will be used to acquire LP units in its parent entity and repay $141.3 million in outstanding debt. Trading is expected to begin on Nasdaq under ticker 'SUJA' on May 7, 2026.

05/07/2026, 12:16 AM • Benzinga

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company focused on blood coagulation disorder treatments, priced its initial public offering at $18.00 per share for 16.75 million shares, raising approximately $301.5 million in gross proceeds. The company's stock is expected to begin trading on Nasdaq under ticker symbol 'COAG' on May 1, 2026, with the offering expected to close on May 4, 2026.

04/30/2026, 6:55 PM • GlobeNewswire

Got $3,000? Palantir Might Be the 1 Defense‑Tech Name Where Trump‑Era Contracts Actually Support a Long‑Term Thesis

Palantir Technologies trades at extreme valuations (60-80x forward revenue) but may justify premium pricing through its embedded position in U.S. defense infrastructure, particularly its Maven AI platform achieving 'program of record' status. The company's U.S. commercial segment grew 137% YoY in Q4 2025, reducing government dependency. However, the stock carries significant downside risk if growth decelerates below guidance, and potential AI regulation could impact autonomous targeting capabilities.

04/16/2026, 11:27 AM • The Motley Fool

CORRECTION - Israel Tech Week Moves Forward in Miami Amid Ongoing War in Israel

Israel Tech Week will hold its 2026 Miami conference April 27-30, positioning itself as one of the few major international tech platforms operating outside Israel this year as many conferences have been postponed or canceled due to the ongoing war. The event expects over 1,500 attendees, including hundreds from Israel and dozens of startups, providing a critical opportunity for Israeli founders and investors to connect with global partners and markets.

04/13/2026, 1:03 AM • GlobeNewswire